Wound testing is generally useful when clinical findings suggest infection and the result could change treatment—not simply because a chronic wound contains bacteria. After cleansing and debridement when appropriate, tissue or a properly collected specimen is usually more informative than a superficial swab.
Most open chronic wounds are colonized. Increased pain, warmth, erythema, swelling, purulent drainage, malodor with deterioration, delayed healing, systemic symptoms, or suspected deeper infection can justify testing after clinical assessment. A clinically uninfected diabetic foot ulcer should not be cultured merely to select antibiotics.
Conventional culture identifies organisms that grow under laboratory conditions and can provide antibiotic susceptibility results. Molecular testing can detect microbial genetic material quickly and may identify additional organisms, but detection does not by itself prove viable organisms are causing infection and often does not replace standard susceptibility testing.
The wound should be cleansed and devitalized surface material removed when safe. For a diabetic foot infection, guidelines prefer an aseptically collected tissue specimen over a superficial swab. Suspected osteomyelitis may require imaging and a bone specimen rather than relying on a wound swab.
Coverage depends on medical necessity, the ordered test, laboratory status, plan rules, and documentation showing how results will guide care. Some molecular panels face additional utilization review. Coverage or authorization never guarantees payment, and antibiotics should be based on the full clinical picture rather than a result alone.
Call 877-545-1300 or request a provider to begin care. Healix360 serves Southern California and Nevada and accepts Medicare Part B and most major insurance plans.